Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Donor-Derived Very-Rapid Manufactured CD19-Specific T Cells for Lymphoid Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation

NCT03579888 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03579888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03579888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Donor-Derived Very-Rapid Manufactured CD19-Specific T Cells for Lymphoid Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
June 26, 2020
Completion date
May 27, 2021
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia with t(v;11q23.3); kmt2a rearranged, recurrent b acute lymphoblastic leukemia, recurrent chronic lymphocytic leukemia, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent mantle cell lymphoma, recurrent non-hodgkin lymphoma, recurrent ph-like acute lymphoblastic leukemia, recurrent primary mediastinal (thymic) large b-cell cell lymphoma, recurrent small lymphocytic lymphoma, refractory b acute lymphoblastic leukemia, refractory chronic lymphocytic leukemia, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory mantle cell lymphoma, refractory non-hodgkin lymphoma, refractory ph-like acute lymphoblastic leukemia, refractory primary mediastinal (thymic) large b-cell cell lymphoma, refractory small lymphocytic lymphoma